

**REMARKS****I. Claim Status**

Claims 1-29 remain in the application. Claim 1 is independent.


Claim 1 has been amended

Claim 30 is new.

**II. Rejection Under 35 U.S.C. § 103**

Claims 1-29 stand rejected under 35 U.S.C. § 103 as allegedly being unpatentable over Blankley et al. (US 5,489,686) taken with Beck et al. (US 6,579,885).

In the Office Action, it is stated that Blankley et al. teach treating urinary disorders at column 3, lines 20-40 with substituted 1,2,3,4-tetrahydroisoquinolines of Formula I.



Applicants respectfully submit that the compounds of Formula 1 disclosed in the Blankley et al. patent are isoquinoline derivatives having a substituted phenyl moiety at the five, six, seven, or eight positions of the isoquinoline core. In contrast, the claims of the present application have a structure wherein the phenyl substitution occurs at the four position of the isoquinoline core.

Accordingly, Applicants submit that Blankley et al. does not render obvious the compounds of claim 1. Further, in addition to having a different structure, the Blankley et al. patent does not

suggest the use of a compound as defined in claim 1 for use in treating urinary incontinence including stress or mixed urinary incontinence. The reference to column 3, lines 20-40, set forth in the Office Action, lists or enumerates a variety of conditions in which urinary output may be decreased. In contrast to claim 1, none of the diseases or conditions disclosed in the Blankley et al. patent suggest the use of the compounds set forth therein for the treatment of urinary incontinence which is generally defined as the involuntary or unintentional loss of urine. The compounds of Beck et al. are described for use in the treatment of various neurological disorders. The Beck et al. does not teach or suggest the use of the compounds for the treatment of incontinence. Since neither the Blankley et al. nor the Beck et al. references alone, or in combination, teach the use of the claimed compounds for treating urinary incontinence, Applicants respectfully submit that the claims are patentable over Blankly et al. and Beck et al., and withdrawal of the rejection and allowance of the claims is respectfully solicited.

### **III. Conclusion**


In view of the amendments and remarks made above, Applicants believe that this application is now in condition for allowance. Reconsideration and allowance of claims 1-30 is respectfully requested.

The Commissioner is authorized to charge any fee or credit any over payment in connection with this communication to our Deposit Account No. 23-0455.

Respectfully submitted,

Date: 6/6/06

By:

  
David R. Kurlansky  
Registration No. 41,505  
Warner-Lambert Company LLC  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel.: (734) 622-7304  
Fax: (734) 622-2928